CLAUDIN 18.2

Competitive landscape | Global therapeutic programs | 9 September 2026

Approved anchors now face ADCs with pivotal results and a growing bispecific pipeline.

	Earlier clinical / Phase 3 pending	Phase 3 underway	Filing / positive Phase 3 readout	Approved in stated market
ANTIBODIES	Osemitamab / TST001 Transcenta Ph3 registered; NYR	ASKB589 AskGene FG-M108 FutureGen	—	VYLOY Astellas US approved
ANTIBODY-DRUG CONJUGATES	ATG-022 | Antengene Ph3 registered; NYR ASP546C / XNW27011 Astellas / Evopoint | Ph1/2 RC118 | RemeGen | Ph1/2 SKB315 | Kelun Ph1; Ph2 registered	SHR-A1904 Hengrui JS107 Junshi BL-M05D1 Baili / SystImmune	IBI343 / TAK-921 Innovent / Takeda China NDA accepted LM-302 LaNova / Sino Bio China NDA accepted AZD0901 / Sone-Ve AstraZeneca Ph3 OS+; PFS not met	—
BISPECIFICS	Givastomig / ABL111 NovaBridge / ABL Bio Ph2 | 4-1BB Spevatamig / PT886 Phanes | Ph1/2 | CD47	ASP2138 Astellas | CD3 QLS31905 Qilu | CD3	—	—
CELL THERAPIES	TAC01-CLDN18.2 Triumvira | Ph1/2	—	—	Satri-cel / CT041 CARsgen China approved

Selected programs, not an exhaustive census. NYR = not yet recruiting. Phase 3 underway includes active follow-up.

Excluded from active map: SOT102; Elevation’s EO-3021. Sources: Gosset CLI + ClinicalTrials.gov + primary disclosures; see workbook.